BioElectronics Submits Back Pain Relief & Medication Use Side Effects Registry Study for Publication

FREDERICK, Md., Sept. 28, 2016 /PRNewswire/ -- BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced neuromodulation medical devices announced that it has submitted a paper: "ActiPatch© Central Sensitization Therapy: A Chronic Back Pain Registry Study of Pain Relief & Analgesic Adverse Effects" for publication. The study reports that the majority of chronic back pain sufferers have less than adequate pain relief and significant side effects from their use of nonprescription and prescription analgesic drugs, including opiates, which impact quality of life.  ActiPatch© use decreased chronic back pain such that the majority of subjects were able to eliminate or reduce their analgesic drug use. 

The Company's prior research published in Pain Management of 5,000+ users' results A UK registry study of the effectiveness of a new over-the-counter chronic pain therapy, Pain Manag. 2015 Nov; 5(6): 413-23, http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35, was one of the Top 5 articles read out of all of the 28 Future Science Group Journals in 2106. Future Science Group is a progressive publisher focused on breakthrough medical biotechnological and scientific research.

About BioElectronics Corporation
BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy; and HealFast® Therapy for dogs, cats and horses. For more information, please visit www.bielcorp.com.

Contact:
Grace Holdings
732-335-1152

SOURCE BioElectronics Corporation

Related Links

http://www.bielcorp.com